Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced ...
AGOURA HILLS, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today that its team members …